You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Atrium dosed its first patient in the Corventus trial of ATR-1072 for PRKAG2 syndrome and expects initial proof-of-concept data in the second half of next year, focused on safety, heart delivery and target knockdown.
Atrium Therapeutics announced new nonclinical results for ATR 1072 in a mouse PRKAG2 syndrome model: a single dose of mATR 1072 reversed cardiac glycogen accumulation and improved hypertrophy and ECG parameters ahead of a November 6, 2026 HCMS presentation.
Atrium Therapeutics dosed the first patient in its Phase 1/2 Corventis trial evaluating ATR 1072 for PRKAG2 syndrome; the trial will enroll approximately 37 participants, with initial proof-of-concept data expected in the second half of 2027.
Atrium Therapeutics corrected its disclosed post-offering shares outstanding to 21,571,507. The October 7, 2026 offering comprises 5,170,384 common shares and pre-funded warrants for up to 1,134,930 shares.
Atrium Therapeutics, Inc. entered an unregistered offering on October 7, 2026, selling 5,170,384 shares and pre-funded warrants for up to 1,134,930 shares, with closing expected on or about October 9, 2026.
